(3aR,5s,6aS)-benzyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate | 130658-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3aR,5s,6aS)-benzyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
• CAS: 130658-20-7
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: IVEHLGJCAUGGRT-WDNDVIMCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.03
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.77
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (3aR,5s,6aS)-benzyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 在 caesium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 21.0h， 生成 (3aR,5r,6aS)-benzyl 5-(4-fluorophenoxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  [EN] N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B
  [FR] COMPOSÉS N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE NR2B

  摘要：

  本发明涉及N-烷基芳基-5-氧基芳基-八氢环戊[c]吡咯NR2B受体负性变构调节剂，用于治疗神经系统疾病，其具有式I，其中R1、R2、L1、L2、X、Y和Y'如所述。在一个方面，描述了式I的化合物以及其药学上可接受的盐、前药、溶剂化合物、水合物、互变异构体或立体异构体，其中：L1是直链或支链的C1-C5烷基，可选地取代一个或多个取代基，所述取代基选自OH、ORIO、NH2、NHRio和N(Rlo)(Rio')的群，但任何碳上不超过一个氧或氮原子。

  公开号：

  WO2016049165A1
• 作为产物：
  描述：

  4-hydroxy-hexahydro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester 在 四氯化碳 、 sodium hydroxide 、 9-borabicyclo[3.3.1]nonane dimer 、 双氧水 、 三苯基膦 作用下， 以 六甲基磷酰三胺 、 二甲基亚砜 为溶剂， 反应 10.0h， 生成 (3aR,5s,6aS)-benzyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  Synthesis and antibacterial activity of new 7-(aminoazabicycloalkanyl)quinolonecarboxylic acids

  摘要：

  A series of novel 7-[amino-substituted azabicycloalkanyl]-6-fluoro-1-substituted quinolinecarboxylic acids (18-53) have been prepared and their antibacterial activities evaluated. These compounds are characterized structurally by a new amino-substituted azabicyclo[3.3.0]octane,-[4.3.0]nonane and -[5.3.0]decane ring systems at the 7-position of quinolonecarboxylic acids. To compare the biological activities of enantiomers, (+)-7[(1S, 5R)- and (-)-7[(1R, 5S)-1-aminomethyl-3-azabicyclo[3.3.0]-octan-3-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid hydrochloride (43, 44) were synthesized and evaluated for antibacterial activity. Compound 43 was more potent than 44 against both Gram-positive and Gram-negative organisms. The structure-activity relationships of these quinolonecarboxylic acids are also discussed.

  DOI：

  10.1016/0223-5234(91)90131-6

文献信息

• N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B
  申请人：Luc Therapeutics, Inc.

  公开号：US10239835B2

  公开（公告）日：2019-03-26

  The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y′ are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio′) provided that no more than one oxygen or nitrogen is attached to any carbon.

  本发明涉及N-烷基芳基-5-氧芳基-辛二氢环戊并[c]吡咯的负异位调节剂，其NR2B受体可用于治疗神经系统疾病，其具有式I，其中R1、R2、L1、L2、X、Y和Y′已在其中描述。在一个方面，描述了式 I 的化合物及其药学上可接受的盐、原药、溶液剂、水合物、同系物或立体异构体，其中：L1 是直链或支链 C1-C5 烷基，可任选被一个或多个选自 OH、ORIO、NH2、NHRio 和 N(Rlo)(Rio′)的取代基取代，条件是任何碳上连接的氧或氮不超过一个。
• N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
  申请人：CADENT THERAPEUTICS, INC.

  公开号：US10781174B2

  公开（公告）日：2020-09-22

  The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y′ are described therein.

  本公开涉及具有式 I 的 N-烷基芳基-5-氧芳基-辛二氢环戊并[c]吡咯 NR2B 受体负异位调节剂，可用于治疗神经系统疾病： 其中R1、R2、L1、L2、X、Y和Y′如其中所述。
• N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B
  申请人：Luc Therapeutics, Inc.

  公开号：US20180111902A1

  公开（公告）日：2018-04-26

  The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y′ are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio′) provided that no more than one oxygen or nitrogen is attached to any carbon.